Why Is Alkermes (ALKS) Up 4.7% Since Last Earnings Report?

Alkermes (ALKS) reported strong Q2 2025 results, with earnings of $0.52 per share and total revenues of $390.7 million, both surpassing consensus estimates of $0.41 and $339 million, respectively. Despite a 2.1% year-over-year decrease in total revenue driven by lower manufacturing and royalty revenues, this was offset by a robust 14% increase in proprietary product sales to $307.2 million. Shares have gained 4.7% since the report, outperforming the S&P 500, though analyst estimates have recently trended downward, resulting in a Zacks Rank #3 (Hold).

Analysis

Alkermes (ALKS) delivered a mixed but overall strong performance in its second quarter of 2025, characterized by a significant beat on both earnings and revenue but underlying compositional shifts that warrant investor attention. The company reported earnings of 52 cents per share against a consensus of 41 cents, and total revenues of $390.7 million comprehensively beat the $339 million estimate. However, this top-line strength was driven entirely by the proprietary drug portfolio, where sales surged 14% year-over-year to $307.2 million, surpassing management's own expectations. Key products Vivitrol, Aristada, and Lybalvi all posted double-digit growth and beat individual sales estimates. This core operational strength was partially offset by a 2.1% decline in total year-over-year revenue, a direct result of a sharp 35.8% drop in manufacturing and royalty revenues. Furthermore, while the stock has gained 4.7% since the report, forward-looking sentiment appears cautious; analyst consensus estimates have been revised downward by 14.21% in the past month. This divergence is also reflected in the company's metrics, which show strong 'A' grades for Growth and Value but a weak 'D' for Momentum, culminating in a Zacks Rank #3 (Hold). The company's cash position improved to $1.05 billion, though operating expenses are rising, with R&D costs up nearly 30% year-over-year.

Key Decisions for Investors

• Investors should weigh the robust 14% year-over-year growth in the proprietary drug portfolio against the significant headwind from a 35.8% decline in royalty revenues and a recent 14.21% downward revision in analyst consensus estimates.
• Given the conflicting signals of a strong quarterly beat versus negative forward estimate revisions and a weak 'D' momentum score, a hold-rated stance may be prudent until the sustainability of core product growth is confirmed.
• Closely monitor the upcoming Q3 results to see if proprietary product sales meet the guided range of $280-$300 million, as this will be a key test of whether core business momentum can offset declining royalty streams and rising R&D expenses.